Himalaya Nutravedics FY26: Profits Surge as the Business Tilts Toward Own Brands

Himalaya Nutravedics India Limited is a young company, incorporated in June 2022, but FY26 shows what happens when a manufacturing-first model starts to produce a brand-led engine. Revenue from operations more than doubled to ₹ 4,306.8 lakhs, up 105.1% year on year. EBITDA rose faster than sales, reaching ₹ 810.3 lakhs, up 171.0%, as margins expanded. Profit after tax climbed to ₹ 739.0 lakhs, up 231.1%, and PAT margin widened to 17.2%.

Under the surface, the year was not only about growth, but also about mix. The company began as a third-party contract manufacturer out of its WHO-GMP facility in Cherlapally, Hyderabad. In FY26, it leaned harder into its own-branded portfolio across classical ayurvedic products, proprietary formulations, and nutraceutical supplements. That shift matters because it changes the economics of the business and how investors should think about sustainability.

Management frames the story as building an integrated platform: manufacturing across multiple dosage forms, expanding the portfolio, and scaling distribution into more states. The numbers suggest the strategy is starting to show operating leverage, even as working capital needs increased.

FY26 in numbers: growth with expanding margins

The income statement captures a year of step change. Revenue moved from ₹ 2,099.7 lakhs in FY25 to ₹ 4,306.8 lakhs in FY26. Costs rose, but profitability rose faster. EBITDA margin improved to 18.8% from 14.2%.

PAT growth was even stronger than EBITDA growth. Profit before tax reached ₹ 748.1 lakhs versus ₹ 224.8 lakhs in FY25. Finance costs remained modest at ₹ 35.0 lakhs in FY26, up slightly from ₹ 31.9 lakhs. Depreciation was lower at ₹ 32.5 lakhs compared with ₹ 42.3 lakhs. The result was a PAT margin of about 17%, a sharp jump from FY25.

Return ratios also improved. ROE stood at 63.9% in FY26, up from 55.0% in FY25 and 37.3% in FY24. ROCE rose to 36.4% from 30.2% in FY25. These ratios reflect rapid profit growth on a net worth base that itself expanded from ₹ 674.8 lakhs in FY25 to ₹ 1,637.6 lakhs in FY26.

The company also highlights a two-year CAGR from FY24 to FY26 that reflects how quickly the base has scaled: revenue CAGR of 72.8%, EBITDA CAGR of 194.3%, and PAT CAGR of 316.5%. This pace is unusual, and it is partly a result of starting from a small base. Still, the margin expansion and higher returns signal that the business is not only scaling volume, but also improving quality of earnings.

One metric needs context: EPS fell from ₹ 24.8 in FY25 to ₹ 18.3 in FY26. At the same time, PAT rose sharply. For investors, that combination usually points to a change in equity base or share count effects. The presentation does not provide share count details, so the correct takeaway is simply that headline profits expanded, while per share earnings moved lower.

What drove the jump: mix shift, manufacturing scale, and distribution reach

Himalaya Nutravedics operates two business segments: its own-branded products and third-party contract manufacturing. FY26 is notable because revenue contribution from own brands surged to 51.1% versus 19.7% in FY25. Third-party manufacturing dropped to 48.9% from 80.4%.

That shift suggests branded products stopped being a side bet and became the main driver. The company sells its brand portfolio through a prescription-led, doctor engagement driven offline model, supported by super-stockists, stockists, and retail pharmacies. This structure can produce repeat demand when products gain practitioner trust, and the company positions that practitioner-driven model as a moat.

At the same time, third-party manufacturing remains important as a stabilizer. The company describes it as ensuring high plant capacity utilization and predictable cash flows, with a meaningful client concentration in Kerala, a major ayurvedic market. In a year when own brands scaled rapidly, the contract business likely provided baseline utilization and helped absorb fixed costs.

Operational data supports the scale-up. Capacity utilization for medicated oil rose to 90% in FY26 from 56% in FY25 and 10% in FY24. Softgel capsule utilization increased to 64% from 34% in FY25. These are large improvements in a short time, and they align with margin expansion.

Product-wise, the revenue mix tilted even more toward ayurvedic products. Ayurvedic products accounted for 94.6% of revenue in FY26, up from 92.1% in FY25 and 79.3% in FY24. Nutraceutical products fell to 5.4% in FY26. Even so, the company continues to highlight nutraceutical formulations in its portfolio, including multivitamin and omega-3 based products.

The distribution footprint expanded to 17 states, with deep penetration in Kerala, Gujarat, Uttar Pradesh, and Telangana. The presentation also notes a dedicated C and F agent arrangement for Uttar Pradesh, Uttarakhand, Jharkhand, and Bihar. This is not just a coverage point; it indicates the company is building logistics reliability in markets that can be difficult to serve.

Geographically, Kerala is the anchor market. The geographic mix shows Kerala at 68.9% in FY26 versus 54.4% in FY25. Even with a wider state footprint, revenue concentration in Kerala increased. That can be a strength, because Kerala is an established ayurvedic consumption market, but it also becomes a risk factor if the company cannot balance growth elsewhere over time.

Balance sheet strength and the working capital question

FY26 ended with total assets of ₹ 2,441.8 lakhs, more than double FY25’s ₹ 1,081.7 lakhs. The largest movements were in current assets linked to growth.

Inventories rose to ₹ 891.5 lakhs from ₹ 328.4 lakhs. Trade receivables increased to ₹ 1,058.7 lakhs from ₹ 564.0 lakhs. In a fast scaling distribution model, this is common, but it shifts attention to cash conversion.

The company’s cash flow from operations was negative at ₹ -383.4 lakhs in FY26, compared with ₹ -139.1 lakhs in FY25. Cash and cash equivalents still rose to ₹ 144.5 lakhs from ₹ 6.7 lakhs, mainly because financing cash flow was positive at ₹ 527.1 lakhs.

Efficiency ratios provide a mixed picture. Debtor days improved to 90 days, down 8 days. But trade receivables turnover slipped to 5.3x from 5.8x, and inventory turnover was 4.3x, down 0.2x. These changes are small, but the underlying absolute build in receivables and inventory is large.

On the liability side, shareholder funds increased to ₹ 1,638.1 lakhs. Borrowings were mainly short-term at ₹ 513.2 lakhs. Debt to equity remained at 0.3x, and net debt to equity was 0.2x. Liquidity also looked comfortable on paper with a current ratio of 2.8x.

The financial position therefore reads as a company funding rapid growth with a mix of operating profits and incremental financing, while cash conversion lags because working capital is being built to support the new scale. For investors, the key point is not that operating cash flow was negative in FY26, but why. The presentation points to expansion of ready finished-goods inventory to prevent stockouts as part of the growth plan, which aligns with the inventory build. Whether cash flow turns positive depends on discipline in receivables and on how quickly the company can move inventory as the footprint expands.

Strategy and moats: manufacturing depth meets a changing market

Management’s narrative is consistent: build quality-led manufacturing, expand the portfolio, grow reach, and now add digital channels to complement a practitioner-led model.

The company positions its competitive moats around integrated manufacturing capabilities and quality compliance. The Hyderabad facility is described as WHO-GMP and ISO certified, with in-house production across softgel capsules, hardgel capsules, tablets, liquid orals, and medicated oils. It also lists quality accreditations including WHO-GMP, ISO 9001:2015, ISO 22000:2018, HACCP, HALAL, and KOSHER.

This matters in ayurvedic and nutraceutical categories because trust is often built through consistency. In a practitioner-driven prescription model, repeated outcomes matter more than mass advertising. The company argues that doctor recommendation anchors demand, and that product efficacy drives retention.

The strategic growth plan for the next phase is more consumer-facing. The company plans to scale D2C and omni-channel distribution through a proprietary website, e-commerce marketplaces, and quick commerce platforms. It also proposes to deploy ₹ 750.00 lakhs from net proceeds toward branding and digital performance marketing, using platforms such as Meta and Google, along with influencer-led content and sponsored listings.

For a company currently concentrated in offline and in an anchor market like Kerala, this is a logical next step. Digital channels can diversify demand geographically and reduce dependence on a few regions. But it also introduces new cost lines, and it may pressure margins in the short term if customer acquisition costs rise faster than repeat purchase. The company’s margin expansion in FY26 provides some cushion, but investors will want to see whether marketing spend translates into sustained branded sales rather than one-time spikes.

Industry context supports the push. The presentation cites structural change toward digital discovery and purchase of health and wellness products. It also highlights low healthcare spending in India at 3.3% of GDP, and a global nutraceuticals industry expected to grow from USD 455.0 billion in 2024 to USD 772.5 billion by 2029. The company’s product areas, including pain management, gut health, women’s wellness, infertility, and neurological support, align with the trend toward preventive care and chronic condition support.

Closing view: FY26 signals execution, FY27 will test cash conversion

Himalaya Nutravedics ended FY26 with a clear theme: execution through mix shift. Revenue doubled, profitability grew faster than sales, and own brands became a majority of revenue. Capacity utilization rose sharply in key formats such as medicated oils and softgels, supporting margin expansion. Returns on equity and capital improved, while leverage remained modest.

The trade-off is visible in cash flow. Operating cash flow stayed negative as receivables and inventory rose with scale. The balance sheet still looks liquid, and debt metrics remain conservative, but the next stage will depend on working capital discipline.

For investors, the takeaway is straightforward. FY26 demonstrates that the company can scale beyond contract manufacturing and build a branded engine with better margins. The strategic plan to add D2C and omni-channel reach fits broader industry shifts. The market will now look for proof that branded growth can broaden beyond Kerala, and that profits can convert into cash as the business matures.